Using anti-proliferative therapy early in HIV treatment to reduce long-term virus persistence
Official title: Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence
Funded at Fred Hutchinson Cancer Center · NIH-11082529 · Data updated 2026-11-12
This study is looking at how certain medications can help people starting HIV treatment by reducing the number of infected cells in the early weeks, which could lead to better health in the long run.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | May 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $846,498 |
| NIH project number | 5R01AI179457-02 |
| Project ID | NIH-11082529 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have recently been diagnosed with HIV and are beginning ART.
✕Less likely to help
Patients who are not newly diagnosed or who have been on ART for an extended period may not benefit from this research.
What this research studies
This research investigates the timing and effectiveness of anti-proliferative therapy in patients initiating antiretroviral therapy (ART) for HIV. It focuses on the critical early weeks of HIV infection, where the proliferation of infected CD4+ T cells contributes to the establishment of a reservoir of latent virus. By administering specific anti-proliferative agents during this window, the study aims to limit the size and diversity of the HIV reservoir, potentially leading to better long-term outcomes for patients. The approach includes testing various small molecular agents to find the most effective combinations for reducing viral persistence.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HIV, potentially reducing the need for lifelong ART.
How similar studies have gone: While the approach of targeting CD4+ T cell proliferation is promising, it is still largely untested in this specific context, making this research novel.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Schiffer, Joshua Tisdell — Fred Hutchinson Cancer Center
- Study coordinator: Schiffer, Joshua Tisdell
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.